111625A4-390B-4D8C-BF80-020062CE9D89
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 4.402102496714849
- age_years
- 34
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.370
- NOTCH_SIGNALING+0.367
- INTERFERON_ALPHA_RESPONSE+0.352
- MYC_TARGETS_V1+0.329
- CHOLESTEROL_HOMEOSTASIS+0.294
- UNFOLDED_PROTEIN_RESPONSE+0.268
- HEDGEHOG_SIGNALING+0.265
- DNA_REPAIR+0.264
- MYC_TARGETS_V2+0.255
- E2F_TARGETS+0.252
Top 10 suppressed
- KRAS_SIGNALING_DN-0.312
- TNFA_SIGNALING_VIA_NFKB-0.290
- COAGULATION-0.250
- HYPOXIA-0.223
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.206
- IL6_JAK_STAT3_SIGNALING-0.202
- MYOGENESIS-0.182
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.181
- INFLAMMATORY_RESPONSE-0.160
- ESTROGEN_RESPONSE_LATE-0.156
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0093DCB6-A7C8-4841-8383-0671A71DDA71 | — | — | 0.908 |
| 2 | 7E7AAFFD-6EEB-4357-88AD-9EB12BB78602 | — | — | 0.891 |
| 3 | 8E62CCB7-9D96-417B-BBCF-01DE08704EDD | — | — | 0.887 |
| 4 | 83BB732E-132F-4677-B70D-5ADE69831226 | — | — | 0.886 |
| 5 | D0F8B6CA-5F3B-4B66-BCC5-72C17325DABF | — | — | 0.876 |
| 6 | 194676E1-632C-4B99-A9C8-80E36DD6C85E | — | — | 0.875 |
| 7 | 4992152D-1D3D-4156-9D80-1B6810AAE78F | — | — | 0.872 |
| 8 | 7465EA24-534F-45A3-8CD3-AD985E574BFF | — | — | 0.870 |
| 9 | 53426017-24F2-4348-BEE1-05E80B6A0E6B | — | — | 0.866 |
| 10 | 604B16D3-7546-4E8C-8443-F1447CC5DFD5 | — | — | 0.865 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.370 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.367 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.352 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.329 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.294 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.268 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.265 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.264 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.255 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.252 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.237 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.236 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.231 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.215 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.206 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.182 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.156 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.128 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.117 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.097 | Idelalisib | — uncovered |